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Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L, the LEAD-4 Study
Investigators. Efﬁcacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin
and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met  TZD). Diabetes Care 2009;32:1224–1230
In the print version of the article listed above, in Table 1, row 3, “C” and “A” representing “Caucasians” and “Asians,” respectively,
have been transposed, thus misrepresenting the population information for this article. Row 3, column 1 should read as follows:
Race (%) (C/B/A/I/O). The online version reﬂects these changes.
American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 2010;33(Suppl. 1):S11–S61
In the print version of the article listed above, errors occurred that involve formatting of Table 12. The corrected version of Table
12 appears below. The online version reﬂects these changes.
Table 12—Reduction in 10-year risk of major CVD endpoints (CHD death/non-fatal MI) in major statin trials, or substudies of major trials,
in diabetic subjects (N  16,032)
Study (ref.)
CVD
prevention Statin dose and comparator Risk reduction
Relative risk
reduction
Absolute risk
reduction
LDL
cholesterol
reduction (%)
4S-DM (211) 2° Simvastatin 20–40 mg vs. placebo 85.7 to 43.2% 50% 42.5% 186 to 119 mg/dl (36%)
ASPEN 2° (216) 2° Atorvastatin 10 mg vs. placebo 39.5 to 24.5% 34% 12.7% 112 to 79 mg/dl (29%)
HPS-DM (212) 2° Simvastatin 40 mg vs. placebo 43.8 to 36.3% 17% 7.5% 123 to 84 mg/dl (31%)
CARE-DM (213) 2° Pravastatin 40 mg vs. placebo 40.8 to 35.4% 13% 5.4% 136 to 99 mg/dl (27%)
TNT-DM (214) 2° Atorvastatin 80 mg vs. 10 mg 26.3 to 21.6% 18% 4.7% 99 to 77 mg/dl (22%)
HPS-DM (212) 1° Simvastatin 40 mg vs. placebo 17.5 to 11.5% 34% 6.0% 124 to 86 mg/dl (31%)
CARDS (234) 1° Atorvastatin 10 mg vs. placebo 11.5 to 7.5% 35% 4.0% 118 to 71 mg/dl (40%)
ASPEN 1° (216) 1° Atorvastatin 10 mg vs. placebo 9.8 to 7.9% 19% 1.9% 114 to 80 mg/dl (30%)
ASCOT-DM (215) 1° Atorvastatin 10 mg vs. placebo 11.1 to 10.2% 8% 0.9% 125 to 82 mg/dl (34%)
Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and non-fatal MI. In this tabulation,
results of the statin on 10-year risk of major CVD endpoints (CHD death/non-fatal MI) are listed for comparison between studies. Correlation between 10-year CVD
riskofthecontrolgroupandtheabsoluteriskreductionwithstatintherapyishighlysigniﬁcant(P0.0007).AnalysesprovidedbyCraigWilliams,PharmD,Oregon
Health & Science University, 2007.
692 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.org